Biotech Startup Rome Therapeutics Raises $77 Million in FundingBy
Company focuses on DNA sequences that don’t produce proteins
Investor Section 32 sees potential in helping to fight disease
Rome Therapeutics Inc., a biotech company focusing on portions of DNA that have been largely overlooked by researchers, raised $77 million in a financing round.
The Cambridge, Massachusetts-based company is exploring DNA sequences that repeat themselves hundreds or thousands of times throughout the human body. Unlike most genes, which have only two copies, repetitive sequences are found in vast stretches of the human genome. Collectively, Rome dubs them the “repeatome.”